Aravive, Inc. - ARAV STOCK NEWS

Aravive, Inc. (Nasdaq: ARAV) announced promising results from the Phase 1b trial of batiraxcept (AVB-500) combined with cabozantinib for treating clear cell renal cell carcinoma (ccRCC). Out of 16 evaluable patients, 44% achieved a partial response, and 88% showed tumor reduction from baseline. Notably, batiraxcept demonstrated no dose-limiting toxicities and an acceptable safety profile. The company plans to initiate a Phase 2 trial by Q4 2021, aiming to further evaluate the efficacy of batiraxcept, which targets the GAS6/AXL signaling pathway, across various cancer types.

Aravive, Inc. (Nasdaq: ARAV) announced promising interim results from the Phase 1b trial of batiraxcept combined with cabozantinib for treating clear cell renal cell carcinoma (ccRCC). As of July 21, 2021, 60% of evaluable patients achieved a partial response, with all showing tumor decrease from baseline. The drug was well-tolerated, exhibiting no dose-limiting toxicities. Further results will be presented on November 13, 2021, at the SITC Annual Meeting. A conference call is scheduled for November 12 to discuss these positive developments.

Aravive, Inc. (Nasdaq: ARAV) announced the initiation of a Phase 1b clinical trial for batiraxcept in pancreatic adenocarcinoma, alongside receiving orphan drug designation from the European Commission for the same drug in platinum-resistant ovarian cancer. The company reported Q3 2021 revenue of $2.4 million, up from $0 in Q3 2020, primarily from a collaboration with 3D Medicines. However, total operating expenses rose to $14.0 million, leading to a net loss of $11.1 million. As of September 30, 2021, cash reserves stood at $67.5 million, expected to last into mid-2022.

Aravive, Inc. (Nasdaq: ARAV) announced new preliminary data from the Phase 1b part of its clinical trial for AVB-500, combined with cabozantinib, targeting clear cell renal cell carcinoma (ccRCC). The data will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting from November 10-14, 2021. The trial, which began in March 2021, aims to enroll approximately 18 patients and assess the treatment's effectiveness and safety, including pharmacokinetics and pharmacodynamics. The main goal is to evaluate progression-free survival in advanced ccRCC patients.

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company, announced participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021. CEO Gail McIntyre and CMO Reshma Rangwala will engage in a virtual fireside chat at 9:20 AM ET and participate in one-on-one meetings. Aravive focuses on developing innovative therapeutics, notably AVB-500, targeting the GAS6-AXL signaling pathway. This first-in-class therapy has FDA Fast Track Designation for platinum-resistant recurrent ovarian cancer and is currently in multiple clinical trials.

Aravive, Inc. (Nasdaq: ARAV) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Gail McIntyre and CMO Reshma Rangwala will engage in a virtual fireside chat, available for viewing on September 13 at 7:00 AM ET. Aravive will also hold one-on-one meetings during the event. The company focuses on developing innovative therapeutics for life-threatening diseases, notably its lead therapeutic, AVB-500, which targets the GAS6-AXL pathway and has received Fast Track Designation for platinum-resistant recurrent ovarian cancer.

Aravive Inc. (Nasdaq: ARAV) has dosed the first patient in its Phase 1b trial of AVB-500, a novel therapy, in combination with gemcitabine and nab-paclitaxel for treating advanced pancreatic adenocarcinoma. This trial aims to assess safety, tolerability, and clinical activity. With pancreatic cancer being a high mortality disease, the study supports a significant unmet medical need. The company is also advancing AVB-500 in other indications, including ovarian and renal cancers, highlighting its robust pipeline and ongoing clinical trials.

Aravive, Inc. (Nasdaq: ARAV) reported positive results from the AVB-500 Phase 1b trial for clear cell renal cell carcinoma, planning to initiate Phase 2 in late 2021. The company is also on track for a Phase 1b/2 trial in pancreatic adenocarcinoma within the same timeframe. Recent milestones included $9 million from 3D Medicines for clinical trial progress. For Q2 2021, Aravive's revenue was $3.8 million, with a net loss of $7.1 million. Cash and equivalents stood at $75.4 million, sufficient to support operations through mid-2022.

Aravive, Inc. (Nasdaq: ARAV) announced participation in the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET. CEO Gail McIntyre and CMO Reshma Rangwala will engage in a virtual fireside chat, alongside one-on-one meetings at the event. Aravive specializes in developing therapeutics for life-threatening diseases, with its lead drug, AVB-500, targeting cancer pathways. The drug has Fast Track Designation for platinum-resistant ovarian cancer and is undergoing Phase 3 trials. Aravive is based in Houston, Texas.